https://news.ontario.ca/en/release/1001269/ontario-accelerating-booster-eligibility-to-adults-aged-50 HMC
Tag: Pfizer
Post
Clarification on WHO statement about COVID-19 vaccine interchangeability
The media has recently reported that a physician associated with the World Health Organization (WHO) suggested that the mixing of vaccines was a ‘dangerous trend’. This was not an official statement by the World Health Organization. The statement was made at a session unrelated to vaccine mixing and was taken out of context by news...
Post
Real World Evidence for COVID-19 Vaccines
Similar to clinical trials, real world cohort and case-control studies find COVID-19 infections are reduced by >90% with two doses of mRNA vaccines. Single doses of either mRNA or AstraZeneca vaccine decreases infections by ~60% and hospitalizations by 70-80%. Vaccine effectiveness appears similar for variants of concern and are safe for pregnant women. HMC
Post
Updated information on AstraZeneca/COVISHIELD COVID-19 vaccines
On June 29, 2021, Health Canada issued a Health Product Risk Communication regarding the AstraZeneca/COVISHIELD COVID-19 vaccine: https://healthycanadians.gc.ca/recall-alert-rappel- avis/hc-sc/2021/75389a-eng.php Health Canada has updated the product monograph for the AstraZeneca and COVISHIELD COVID-19 vaccines to add capillary leak syndrome as a potential side effect following vaccination. Patients with a history of capillary leak syndrome should not...
Post
Second dose of COVID-19 Vaccination
NACI has provided updated recommendations on COVID-19 vaccine schedules. For those who have received a first dose of an AstraZeneca vaccine, an mRNA vaccine is preferred for the second dose due to emerging evidence suggesting better immune response, and, to mitigate the risk of VITT(Vaccine-Induced Thrombotic Thrombocytopenia) from viral vector vaccines. HMC
Post
Second Dose COVID-19 Vaccine Type-Interchangeability, Updated on June3, 2021
NACI recommends that persons who received a first dose of the AstraZeneca/COVISHIELD vaccine may receive either AstraZeneca/COVISHIELD vaccine or an mRNA vaccine (Pfizer-BioNTech or Moderna) for their second dose, unless contraindicated. On June 1, the Public Health Agency of Canada released updated recommendations from the National Advisory Committee on Immunization (NACI) on the interchangeability of authorized...
Post
Youth aged 12-17 will be eligible to register to receive the Pfizer COVID-19 vaccine as of May 31
Stay in contact with Peel Public Health for further details. HMC
Post
All Peel residents aged 18+ are now eligible to receive their COVID-19 vaccine
Effective May 6, all Peel residents aged 18 or older are eligible for vaccination, including those who do not live in provincially designated hot spots. Please note that in order to be eligible, individuals must be at least 18 years of age at the time of their vaccination. Eligible residents can book appointments at any of Peel...
Post
Interchangeability of COVID-19 vaccines
As per the Ministry of Health’s guidance on the Administration of the AstraZeneca COVID-19/COVISHIELD vaccine, individuals who have received one dose of the AstraZeneca/COVIDSHIELD vaccine, should receive a second dose of the AstraZeneca/COVISHIELD vaccine to complete their vaccination series. HMC
Post
COVID-19 Vaccination of the Senior 65+ Population
Peel residents aged 65-69 are now eligible to get vaccinated for COVID-19 at hospital clinics. Appointments for the 65-69 age group will also be expanded to Peel Public Health community clinic sites in the coming days. In alignment with the Ministry’s Guidance for Prioritization of Phase 2 Populations for COVID-19 Vaccination, individuals with the following conditions, along...
Post
More COVID-19 Vaccine Info
Dear Patients, As you all know, the first vaccines are being given to higher risk people and health care workers. But we look forward to when we will have access to the vaccine. We do not yet know the place or the timing and we will communicate this when we do. Some questions have arisen that...
Post
COVID-19 Vaccines
Dear community members and families, In the last few weeks, we have seen significant movement in our understanding of the COVID-19 vaccines. As of today, here is what we know: The vaccines are safe The vaccines approved for use in Canada work by sending a message to our body’s immune system to stimulate our natural immune response....
Post
Answering Patient Questions about COVID-19 Vaccines
Dear Patients, As you all know, the first vaccines are being given to higher-risk people and healthcare workers. But we look forward to when you all will have access to the vaccine. We do not yet know the place or the timing and we will communicate this when we do. Appropriate steps taken – The...
Post
3 Approved COVID-19 Vaccines Efficacy
Interim results of two large randomized, placebo-controlled trials (RCTs) demonstrate ~95% relative efficacy in preventing COVID-19 (Pfizer, Moderna). The AstraZeneca/Oxford vaccine has ~70% relative efficacy. Absolute benefits will vary with baseline risk and time but if annual risk of developing COVID-19 is 20%, then vaccine would decrease risk to 1% (6% with AstraZeneca/Oxford). These vaccines...
Post
More Info about COVID-19 Vaccine
https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html
Post
Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies
Two individuals in the U.K. reported severe allergic reactions to Pfizer BioNTech’s COVID-19 vaccine on December 8, 2020. As vaccine roll-out begins in Canada, Canadians may be wondering about the risks of allergic reactions and if they should receive this vaccine if they have allergies to foods or other medications. Health Canada has reviewed the...
Post
Health Canada updates Canadians on shortage situation involving EpiPen (0.3 mg) auto-injectors
Following Health Canada’s most recent communication regarding a shortage of EpiPen (0.3 mg) and EpiPen Jr (0.15 mg) auto-injectors, Pfizer Canada has advised Health Canada that supply of EpiPen in the 0.3 mg format is expected to be very limited at pharmacies during the month of August. Contact your pharmacies for further updates. HMC
Post
Shortage of EpiPen (0.3 mg) auto-injector in Canada
Pfizer Canada has advised Health Canada that there is currently a shortage of EpiPen auto-injectors in the 0.3 mg format (DIN 00509558). The shortage is reported to be due to a manufacturing disruption and is currently anticipated to be resolved by March 2, 2018. According to Pfizer, the shortage does not impact EpiPen Jr (0.15...